Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Fifth Third Bancorp reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Sanofi aims to boost competition in the atopic dermatitis market, following Dupixent's success, with new treatments like SAR444656 and amlitelimab in development.

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

"Sanofi to increase competition in atopic dermatitis market after Dupixent success" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.